Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
Delayed Quote. Delayed Nyse - 09/24 04:10:00 pm
43.94 USD   -0.57%
09/25PFIZER : Israel says US booster plan supports its own aggressive push
AQ
09/25AP NEWS IN BRIEF AT 12 : 04 a.m. EDT
AQ
09/24PFIZER : Guest lineups for the Sunday news shows
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer epilepsy drug prices were 'unfairly high,' UK review finds

08/05/2021 | 06:24am EDT
FILE PHOTO: Pfizer logo in Manhattan, New York

(Reuters) -Britain's competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law by charging the country's public health service "unfairly high" prices for an epilepsy drug, after being asked to reassess a previous fine.

The drugmakers made use of a loophole so that the capsules, called Epanutin before September 2012, were not subject to price regulation for branded drugs, the Competition and Markets Authority (CMA) found in its provisional review https://www.gov.uk/government/news/cma-accuses-pharma-firms-of-illegal-pricing disclosed on Thursday.

In 2016, the CMA fined https://www.reuters.com/article/us-pfizer-britain-fine-idUSKBN13W0VT Pfizer and Flynn roughly 90 million pounds ($125 million) for hiking prices by as much as 2,600% to 67.50 pounds for a 100mg pack.

However, the companies in 2018 won an appeal https://www.reuters.com/article/uk-pfizer-britain-fine-idUKKCN1J327D against the penalty, and the Competition Appeal Tribunal referred the matter back to the CMA.

The watchdog said that spending by Britain's National Health Service (NHS) on the capsules, containing phenytoin sodium, jumped to roughly 50 million pounds in 2013 from about 2 million pounds just a year earlier.

The CMA has been cracking down on drug price hikes in Britain. Last month, it fined more than 10 drug firms https://www.reuters.com/world/uk/britain-fines-drugmakers-360-million-overcharging-nhs-2021-07-15 a record 260 million pounds in total for a 10,000% surge in prices of a life-saving steroid.

"As Pfizer and Flynn were the dominant suppliers of the drug in the UK, the NHS had no choice but to pay unfairly high prices for this vital medicine," the CMA said in a statement after it gathered more evidence and reviewed its previous case.

Pfizer said it was co-operating with the regulator. Flynn did not immediately respond to Reuters' request for comment.

"Ensuring a sustainable supply of our products to UK patients is of paramount importance to Pfizer and was at the heart of our decision to divest the product in 2012," U.S. based Pfizer said in an e-mailed statement.

In September 2012, Pfizer sold the UK distribution rights for Epanutin to Flynn. Before that, Pfizer was selling phenytoin sodium capsules to UK wholesalers and pharmacies, the CMA said.

The regulator added that Pfizer and Flynn can respond to its findings before a formal decision is reached.

($1 = 0.7205 pounds)

(Reporting by Pushkala Aripaka in Bengaluru Editing by Rashmi Aich and Mark Potter)

By Pushkala Aripaka


ę Reuters 2021
All news about PFIZER, INC.
09/25PFIZER : Israel says US booster plan supports its own aggressive push
AQ
09/25AP NEWS IN BRIEF AT 12 : 04 a.m. EDT
AQ
09/24PFIZER : Guest lineups for the Sunday news shows
AQ
09/24ADRs End Lower; WPP, BioNTech Among Companies Actively Trading
DJ
09/24SCHOOL DISRUPTION, 'LONG COVID,' ALL : Tam
AQ
09/24PFIZER : OPKO Health Get FDA Extension for Review of Somatrogon Biologics License Applicat..
MT
09/24Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application ..
CI
09/24PFIZER : Residents of Saugeen First Nation given expired COVID-19 Pfizer vaccine for weeks
AQ
09/24WALMART : Sam's Club to Administer Pfizer COVID-19 Booster Shots
MT
09/24MODERNA : U.S. administers 388.6 mln doses of COVID-19 vaccines - CDC
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 115 M - -
Net income 2021 18 438 M - -
Net Debt 2021 28 980 M - -
P/E ratio 2021 13,0x
Yield 2021 3,59%
Capitalization 246 B 246 B -
EV / Sales 2021 3,39x
EV / Sales 2022 3,97x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 43,94 $
Average target price 45,19 $
Spread / Average Target 2,84%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.20.05%246 358
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037
ABBVIE INC.-0.07%189 211